Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production

Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

A cell culture model for T lymphocyte clonal anergy

Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786

A Theory of Self-Nonself Discrimination

Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755

CTLA-4 is a second receptor for the B cell activation antigen B7.

Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685

A new member of the immunoglobulin superfamily—CTLA-4

Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Abatacept therapy and safety management

Pham, T., Claudepierre, P., Constantin, A., Fautrel, B., Gossec, L., Gottenberg, J., Goupille, P., HACHULLA, E., Masson, C., Morel, J., et al. (2009) · Joint Bone Spine · doi:10.1016/s1297-319x(09)74520-8 · Cited by 36

Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples

Powell, D. J., Parker, L. L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000170363.22585.5a · Cited by 36

CTLA-4 Blockade: Autoimmunity As Treatment

Kapadia, D., & Fong, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.012 · Cited by 36

Mouse Model for Pre‐Clinical Study of Human Cancer Immunotherapy

Ya, Z., Hailemichael, Y., Overwijk, W. W., & Restifo, N. P. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im2001s108 · Cited by 35

GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses

Kwek, S. S., Kahn, J. G., Greaney, S. K., Lewis, J., Cha, E., Zhang, L., Weber, R. W., Leonard, L., Markovic, S. N., Fong, L. H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1101204 · Cited by 35

The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer

Noel, G. L., Fontsa, M. L., & Willard-Gallo, K. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.003 · Cited by 35

The immunotherapeutic role of indoleamine 2,3‐dioxygenase in head and neck squamous cell carcinoma: A systematic review

Lin, D. J., Ng, J. C. K., Huang, L., Robinson, M., O’Hara, J., Wilson, J. A., & Mellor, A. L. (2021) · Clinical Otolaryngology · doi:10.1111/coa.13794 · Cited by 35

The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines

Assudani, D., Horton, R. B. V., Mathieu, M. G., McArdle, S., & Rees, R. C. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0154-6 · Cited by 35

T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity

Foell, J., & Hewes, B. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006841 · Cited by 35

The treatment of melanoma with an emphasis on immunotherapeutic strategies

Jack, A., Boyes, C., Aydin, N., Alam, K., & Wallack, M. K. (2006) · Surgical Oncology · doi:10.1016/j.suronc.2006.05.003 · Cited by 35

Adverse Consequences of Immunostimulation

Ponce, R. A. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897920 · Cited by 35

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.

Murillo, O., Arina, A., Tirapu, I., Alfaro, C., Mazzolini, G. D., Palencia, B., de Cerio, A. L.-D., Prìeto, J., Bendandi, M., & Melero, I. (2003) · PubMed · Cited by 35

Immunotherapy for gynaecological malignancies

Coukos, G., Conejo-Garcia, J. R., Roden, R. B. S., & Wu, T. ‐. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.9.1193 · Cited by 35

Immunotherapy Resistance in Glioblastoma

Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34

Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy

Roliński, J., & Hus, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.865094 · Cited by 34

Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies

Choudhury, N. J., & Nakamura, Y. (2015) · Cancer Science · doi:10.1111/cas.12862 · Cited by 34

Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma

Chaoul, N., Mancarella, S., Lupo, L., Giannelli, G., & Dituri, F. (2020) · Cancers · doi:10.3390/cancers12030627 · Cited by 34

Regulatory T cell-mediated suppression: potential role of ICER

Bodor, J., Fehervari, Z. T., Diamond, B., & Sakaguchi, S. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0706474 · Cited by 34

Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes

Rossi, G. R., Unfer, R. C., Seregina, T., & Link, C. J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0667-4 · Cited by 34

Tumor Vaccines for Breast Cancer

Anderson, K. S. (2009) · Cancer Investigation · doi:10.1080/07357900802574421 · Cited by 34

Do regulatory T-cells play a role in AIDS pathogenesis?

Boasso, A., Vaccari, M., Nilsson, J., Gm, S., Andersson, J., Cecchinato, V., Chougnet, C. A., & Franchini, G. (2006) · PubMed · Cited by 34

Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models

Liu, Y., Tuve, S., Persson, J., Beyer, I., Yumul, R., Li, Z. Y., Tragoolpua, K., Hellström, K. E., Roffler, S. R., & Lieber, A. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.8 · Cited by 33

The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses

Chakraborty, M., Schlom, J., & Hodge, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0291-6 · Cited by 33

Chronic Immune Therapy Induces a Progressive Increase in Intratumoral T Suppressor Activity and a Concurrent Loss of Tumor-Specific CD8+ T Effectors in her-2/neu Transgenic Mice Bearing Advanced Spontaneous Tumors

Nair, R. E., Kilinc, M. O., Jones, S. A., & Egilmez, N. K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7325 · Cited by 33

In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis

Lin, H.-H., Gutenberg, A., Chen, T., Tsai, N., Lee, C., Cheng, Y.-C., Cheng, W., Tzou, Y.-M., Caturegli, P., & Tzou, S. (2017) · Scientific Reports · doi:10.1038/srep43492 · Cited by 33

Molecular Markers for Colorectal Cancer

Wright, M., Beaty, J. S., & Ternent, C. A. (2017) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.01.014 · Cited by 33

A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer

McAllister, M. J., Underwood, M. A., Leung, H. Y., & Edwards, J. (2018) · Translational research · doi:10.1016/j.trsl.2018.11.004 · Cited by 33

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody

Camacho, L. H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.371 · Cited by 33

Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy

Besser, M. J., Schallmach, E., Oved, K., Treves, A. J., Markel, G., Reiter, Y., & Schachter, J. (2009) · Cytotherapy · doi:10.1080/14653240802590391 · Cited by 33

Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells.

Loke, P., & Allison, J. P. (2004) · Arthritis Research · doi:10.1186/ar1225 · Cited by 34

Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes

Shigematsu, Y., Hanagiri, T., Shiota, H., Kuroda, K., Baba, T., Ichiki, Y., Yasuda, M., Uramoto, H., Takenoyama, M., Yasumoto, K., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.815 · Cited by 33

T regulatory cell markers in oral squamous cell carcinoma: Relationship with survival and tumor aggressiveness

Moreira, G., Fulgêncio, L. B., Mendonça, E. F., Leles, C. R., Batista, A. C., & Silva, T. A. (2009) · Oncology Letters · doi:10.3892/ol_00000023 · Cited by 33

Emerging therapies for melanoma

Katipamula, R., & Markovic, S. N. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.553 · Cited by 33

Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response

Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136045 · Cited by 32

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

Maccalli, C., Giannarelli, D., Capocefalo, F., Pilla, L., Fonsatti, E., Giacomo, A. M. D., Parmiani, G., & Maio, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1071007 · Cited by 32

Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge

Lynch, H. T., Lanspa, S. J., Shaw, T. G., Casey, M. J., Rendell, M., Stacey, M. L., Townley, T. A., Snyder, C., Hitchins, M. P., & Wilson, J. (2017) · Familial Cancer · doi:10.1007/s10689-017-0053-3 · Cited by 35

CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with −318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients

Duan, S., Zhang, G., Han, Q., Zhu, L., Liu, Z., Chen, J., Lv, Y., Li, N., Wang, Y., Li, M., et al. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0660-7 · Cited by 32

Invariant natural killer T cells and immunotherapy of cancer

Molling, J. W., Moreno, M., van der Vliet, H. J., van den Eertwegh, A. J. M., Scheper, R. J., Blomberg, B. M. E. V., & Bontkes, H. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.025 · Cited by 32

Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma

Peggs, K. S., & Quezada, S. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.144 · Cited by 32

Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response

Scott, I. (2005) · Frontiers in bioscience · doi:10.2741/1575 · Cited by 32

Induction of regulatory T cell–resistant helper CD4+ T cells by bacterial vector

Nishikawa, H., Tsuji, T., Jäger, E., Briones, G., Ritter, G., Old, L. J., Galán, J. E., Shiku, H., & Gnjatic, S. (2007) · Blood · doi:10.1182/blood-2007-09-113761 · Cited by 32

Dendritic Cell-Based Tumor Vaccines and Antigen Presentation Attenuators

Evel-Kabler, K., & Chen, S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.009 · Cited by 32

Rational peptide-based tumour vaccine development and T cell monitoring

Scheibenbogen, C., Letsch, A., Schmittel, A. H., Asemissen, A.-M., Thiel, E., & Keilholz, U. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.006 · Cited by 32

New approaches in metastatic melanoma: biological and molecular targeted therapies

Lejeune, F. J., Rimoldi, D., & Speiser, D. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.701 · Cited by 32

Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines

Ruiz, R., Hunis, B., & Raez, L. E. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0400-6 · Cited by 31

Immune Checkpoint Blockade in Breast Cancer Therapy

Bu, X., Yao, Y., & Li, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_18 · Cited by 31

The 100 top-cited studies in cancer immunotherapy

Zhang, Y., Quan, L., & Du, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1623234 · Cited by 31

The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities

Amôr, N. G., Santos, P. S. D. S., & Campanelli, A. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636544 · Cited by 32

Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation

Farkas, A. M., & Finn, O. J. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.003 · Cited by 31

Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives

Baccalà, R., González‐Quintial, R., Dummer, W., & Theofilopoulos, A. N. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0196-9 · Cited by 31

Anti–human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies

May, K. F., Roychowdhury, S., Bhatt, D., Kocak, E., Bai, X., Liu, J.-Q., Ferketich, A. K., Martin, E. W., Caligiuri, M. A., Zheng, P., et al. (2004) · Blood · doi:10.1182/blood-2004-07-2561 · Cited by 31

Lack of Sprouty 1 and 2 enhances survival of effector CD8 + T cells and yields more protective memory cells

Shehata, H. M., Khan, S., Chen, E., Fields, P. E., Flavell, R. A., & Sanjabi, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808320115 · Cited by 31

Therapeutic Vaccines for Melanoma

Faries, M. B., & Morton, D. L. (2005) · BioDrugs · doi:10.2165/00063030-200519040-00004 · Cited by 31

Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity

Sittler, T., Zhou, J. M., Park, J., Yuen, N. K., Sarantopoulos, S., Mollick, J. A., Salgia, R., Giobbie‐Hurder, A., Dranoff, G., & Hodi, F. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4782 · Cited by 31

Therapeutic opportunities in the B7/CD28 family of ligands and receptors

Carreno, B. M., Carter, L., & Collins, M. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.003 · Cited by 31

Molecular mechanisms of ferroptosis and its antitumor applications in natural products

Yu, D., Wang, Q., Zhang, Q., Cai, M., Liu, S., & Zhang, W. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023120 · Cited by 30

High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?

Amin, A., & White, R. L. (2013) · PubMed · Cited by 30

Immunotherapies: The Blockade of Inhibitory Signals

Wu, Y., Liang, J., Zhang, W., Tanaka, Y., & Sugiyama, H. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.5273 · Cited by 32

Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy

Hinrichs, C. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1294 · Cited by 30

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

Aya, F., Fernández-Martínez, A., Gaba, L., Victoria, I., Tosca, M., Pineda, E., Gascón, P., Prat, A., & Arance, A. M. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1514-0 · Cited by 30

Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy

Deligiorgi, M. V., Siasos, G., Vergadis, C., & Trafalis, D. T. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106427 · Cited by 30

New Strategies in Melanoma: Entering the Era of Combinatorial Therapy

Sullivan, R. J., & Flaherty, K. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1650 · Cited by 30

Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance

Koon, H. B., & Atkins, M. B. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.1.79 · Cited by 30

CTLA-4 +49A>G Polymorphism Is Associated with Advanced Non-Small Cell Lung Cancer Prognosis

Song, B., Liu, Y., Liu, J., Song, X., Wang, Z., Wang, M., Zhu, Y., & Han, J. (2011) · Respiration · doi:10.1159/000329345 · Cited by 31

Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells

Jacob, J. B., Kong, Y.-C. M., Meroueh, C., Snower, D. P., David, C. S., Ho, Y.-S., & Wei, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4755 · Cited by 30

Immunotherapy‐Induced Colitis: An Emerging Problem for the Hospitalist

Marin-Acevedo, J. A., Harris, D. M., & Burton, M. C. (2018) · Journal of Hospital Medicine · doi:10.12788/jhm.2925 · Cited by 30

Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines

Miska, J. M., Lui, J. B., Toomer, K. H., Devarajan, P., Cai, X., Houghton, J., Lopez, D. M., Abreu, M. T., Wang, G., & Chen, Z. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171971 · Cited by 32

Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review

Azevedo, R., Ferreira, J. A., Peixoto, A., Neves, M., Sousa, N., Lima, Á., & Santos, L. L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.002 · Cited by 30

Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology

Laheru, D. A., Pardoll, D. M., & Jaffee, E. M. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0151 · Cited by 30

Immunotherapeutic peptide vaccination with leukemia-associated antigens

Rusakiewicz, S., & Molldrem, J. J. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.07.005 · Cited by 30

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1

Dillen, A., Bui, I., Jung, M., Agioti, S., Zaravinos, A., & Bonavida, B. (2024) · Cancers · doi:10.3390/cancers16061237 · Cited by 29

Ipilimumab in the treatment of melanoma

Trinh, V. A., & Hwu, W. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.675325 · Cited by 29

Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges

Pilla, L., & Maccalli, C. (2018) · Biomedicines · doi:10.3390/biomedicines6030076 · Cited by 29

Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects

Lombardi, A., & Mondelli, M. U. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15449 · Cited by 30

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

Shah, N., Jacob, J. M., Househ, Z., Shiner, E. K., Baird, L., & Soudy, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0727-5 · Cited by 29

Recent advance in nanomaterials for cancer immunotherapy

Hou, Y., Liu, Y., Tang, C., Tan, Y., Zheng, X., Deng, Y., He, N., & Li, S. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.134145 · Cited by 29

Modulation of CTLA-4 and GITR for Cancer Immunotherapy

Avogadri, F., Yuan, J. D., Yang, A. S., Schaer, D., & Wolchok, J. D. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_49 · Cited by 29

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

Comı́n-Anduix, B., Sazegar, H., Chodon, T., Matsunaga, D. R., Jalil, J., von Euw, E., Escuin-Ordinas, H., BALDERAS, R. S., Chmielowski, B., Gómez-Navarro, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012711 · Cited by 29

Immunotherapeutic Strategies for High-Risk Bladder Cancer

Sharma, P., Old, L. J., & Allison, J. P. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.12.004 · Cited by 29

CTLA4 Silencing with siRNA Promotes Deviation of Th1/Th2 in Chronic Hepatitis B Patients

Yu, Y., Wu, H., Tang, Z., & Zang, G. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.17 · Cited by 29

Anti-allergic Psidium guajava extracts exert an antitumor effect by inhibition of T regulatory cells and resultant augmentation of Th1 cells.

Seo, N., Ito, T., Wang, N., Yao, X., TOKURA, Y., Furukawa, F., Takigawa, M., & Kitanaka, S. (2005) · PubMed · Cited by 29

Immune Regulatory Antibodies

Wolchok, J. D., Yang, A. S., & Weber, J. S. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3381 · Cited by 28

The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0409 · Cited by 28

Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma

Panek, W. K., KANE, J. R., Young, J. S., Rashidi, A., Kim, J. W., Kanojia, D., & Lesniak, M. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20810 · Cited by 28

Aetiology and pathogenesis of paraneoplastic autoimmune disorders

Geng, G., Yu, X., Jiang, J., & Yu, X. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102422 · Cited by 28

The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL

Simatou, A., Sarantis, P., Koustas, E., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207570 · Cited by 28

Role of Cytogenetics in Management of Uveal Melanoma

Shields, J. A. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.3.416 · Cited by 28

Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal

Batista-Duharte, A., Téllez-Martínez, D., Portuondo, D. L., & Carlos, I. Z. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.026 · Cited by 28

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

de Olza, M. O., Oliva, M., Hierro, C., Matos, I. G., Martín-Liberal, J., & Garralda, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy225 · Cited by 28

Regulatory T Cells in Cancer

Piconese, S., & Colombo, M. P. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_4 · Cited by 28

Coinhibitory molecules in cancer biology and therapy

D, S. M. M., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 27

Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient

Hamid, M. A., Peng, Y., & Dong, T. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0468-x · Cited by 27

Cancer immunotherapy from biology to nanomedicine

Abdelbaky, S. B., Ibrahim, M. T., Samy, H., Mohamed, M., Mohamed, H., Mustafa, M., Abdelaziz, M. M., Forrest, M. L., & Khalil, I. A. H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.025 · Cited by 28

Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma

Aboul‐Fettouh, N., Morse, D., Patel, J., & Migden, M. R. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.11s2a169s · Cited by 28

Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications

Ge, S., Zhao, Y., Liang, J., He, Z., Li, K., Zhang, G., Hua, B., Zheng, H., Guo, Q., Qi, R., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03211-w · Cited by 28

Immunomodulation

Gea‐Banacloche, J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_92 · Cited by 27

The course of melanoma-associated vitiligo: report of a case

Daneshpazhooh, M., Shokoohi, A., Dadban, A., & Raafat, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222590.68234.1d · Cited by 27

The antibody response against MART ‐1 differs in patients with melanoma‐associated leucoderma and vitiligo

Teulings, H. E., Willemsen, K. J., Glykofridis, I. E., Krebbers, G., Komen, L., Kroon, M. W., Kemp, E. H., Wolkerstorfer, A., van der Veen, J. P. W., Luiten, R. M., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12294 · Cited by 27

The Tumor/Immune Interface: Clinical Evidence of Cancer Immunosurveillance, Immunoediting and Immunosubversion

Block, M. S., & Markovic, S. N. (2009) · American Journal of Immunology · doi:10.3844/ajisp.2009.29.49 · Cited by 29

Adjuvant Therapy of Melanoma

Shah, G., & Chapman, P. B. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318074dfd4 · Cited by 27

Overcoming immunological tolerance to melanoma: targeting CTLA-4

HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492

CTLA‐4 to overcome immunological tolerance to melanoma

Hodi, F. S. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01383.x

Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma

Robinson, M. R., Chan, C. C., Yang, J. C.-H., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159

Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer

Blansfield, J., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C. L., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 354